About Joshua Lin, MD, MPH, SCD
Clinical Interests:
- Epidemiology
- Hospital Medicine
Treats:
- Adult
Languages:
- Mandarin Chinese
Locations
Mass General Medicine Unit
55 Fruit St.
Boston, MA 02114
Phone: 617-724-3874
Medical Education
- MD, National Taiwan University Medical College
- Residency, Jacobi Medical Center
- Fellowship, Harvard T.H. Chan School of Public Health **
American Board Certifications
- Internal Medicine, American Board of Internal Medicine
Accepted Insurance Plans
- Aetna
- Beech Street
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Cigna
- Commonwealth Care Alliance
- Coventry
- Fallon Health
- Harvard Pilgrim Health Care
- Humana
- Maine Community Health Options
- Mass General Brigham Health Plan
- MassHealth
- Medicaid CT
- Medicaid ME
- Medicaid NH
- Medicaid NY
- Medicaid RI
- Medicaid VT
- Medicare
- Medicare ACO
- Multiplan
- Railroad Medicare
- Senior Whole Health
- TriCare
- Tufts Health Plan
- Unicare
- United Health Care
- WellSense
- WellSense NH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
Dr. Lin is a Pharmacoepidemiologist in the Division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham and Women’s Hospital and a practicing hospitalist at the Massachusetts General Hospital. He is an Assistant Professor at Harvard Medical school and the Executive Director of the Mass General Brigham (MGB) Center for Integrated Healthcare Data Research. In this role, he has built a highly valuable research database, linking multiple health insurance claims data with a variety of clinical data from electronic health records of the MGB institutions. Leading a team of investigators, research scientists, and administrators, he has built an efficient infrastructure that makes these rich data sources readily available for researchers at Harvard Medical School to facilitate scientific discovery. As Principal Investigator of three NIH-funded R01 research projects (1R01LM012594, 1RF1AG063381 [1R01AG063381], and 1R01LM013204), his research has focused on optimal prescribing in vulnerable populations using large routine-care databases and to establish a rigorous and generalizable framework to optimize validity and precision of comparative effectiveness research with detailed evaluation of treatment effect heterogeneity using electronic health records and insurance claims data.